拉索昔芬联合阿贝西利治疗既往治疗后进展的转移性ER+/HER2-乳腺癌伴ESR1突变女性的开放标签、II期、多中心研究:ELAINE 2
ELAINE 2是一项开放标签II期多中心试验,评估拉索昔芬5 mg/日联合阿贝西利150 mg每日两次治疗29例ESR1突变、ER+/HER2-转移性乳腺癌患者,几乎所有患者既往接受过CDK4/6抑制剂。主要终点为安全性/耐受性,联合方案耐受良好,中位无进展生存期为56.0周(95%CI 31.9周至不可估计),24周临床获益率为65.5%,18例可测量病灶患者客观缓解率为55.6%。
要点
- 拉索昔芬联合阿贝西利在ESR1突变ER+/HER2-转移性乳腺癌中耐受良好,主要为1/2级不良事件。
- 中位无进展生存期为56.0周(95%CI 31.9周至不可估计,约13个月),24周临床获益率为65.5%。
- 可测量病灶患者客观缓解率为55.6%(95%CI 33.7%至75.4%)。
核心结论
- 拉索昔芬联合阿贝西利安全性可接受、耐受良好,在既往CDK4/6抑制剂治疗后进展的ESR1突变、ER+/HER2-转移性乳腺癌女性中表现出有意义的抗肿瘤活性。
- 拉索昔芬治疗后ESR1突变循环肿瘤DNA下降与临床缓解一致,提示靶点结合。
- 若ELAINE 2结果在已启动的III期ELAINE 3试验中得到证实,这些数据可能改变实践并帮助解决关键未满足需求。
研究设计与样本
- 开放标签、II期、多中心ELAINE 2试验(NCT04432454)。
- 入组29例ESR1突变、ER+/HER2-转移性乳腺癌女性,中位年龄60岁。
- 患者接受拉索昔芬5 mg/日联合阿贝西利150 mg每日两次,直至疾病进展或毒性。
- 除1例外,其余患者既往接受过CDK4/6抑制剂(中位持续时间2年)。
- 主要终点为安全性/耐受性;次要终点包括无进展生存期、临床获益率和客观缓解率。
主要发现
- 联合方案耐受良好,主要为1/2级治疗中出现的不良事件,最常见为腹泻、恶心、乏力(疲劳)和呕吐。
- 1例既往未接受CDK4/6抑制剂的患者因2级腹泻终止治疗;研究期间无死亡发生。
- 中位无进展生存期为56.0周(95%CI 31.9周至不可估计;约13个月);6、12和18个月无进展生存率分别为76.1%、56.1%和38.8%。
- 24周临床获益率为65.5%(95%CI 47.3%至80.1%)。
- 18例可测量病灶患者中客观缓解率为55.6%(95%CI 33.7%至75.4%);21/26例(80.8%)患者ESR1突变循环肿瘤DNA等位基因分数从基线至第4周下降。
关键数值与推荐
- 拉索昔芬5 mg/日联合阿贝西利150 mg每日两次,直至疾病进展或毒性。
- 中位无进展生存期56.0周(95%CI 31.9周至不可估计)。
- 6、12和18个月无进展生存率分别为76.1%、56.1%和38.8%。
- 24周临床获益率65.5%(95%CI 47.3%至80.1%)。
- 可测量病灶患者客观缓解率55.6%(95%CI 33.7%至75.4%);ESR1突变循环肿瘤DNA等位基因分数下降者21/26例(80.8%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acquired ESR1 mutations in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) drive treatment resistance and tumor progression; new treatment strategies are needed. Lasofoxifene, a next-generation, oral, endocrine therapy and tissue-specific ER antagonist, provided preclinical antitumor activity, alone or combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in ESR1-mutated mBC. PATIENTS AND METHODS: In the open-label, phase II, ELAINE 2 trial (NCT04432454), women with ESR1-mutated, ER+/human epidermal growth factor receptor 2-negative (HER2-) mBC who progressed on prior therapies (including CDK4/6i) received lasofoxifene 5 mg/day and abemaciclib 150 mg b.i.d until disease progression/toxicity. The primary endpoint was safety/tolerability. Secondary endpoints included progression-free survival (PFS), clinical benefit rate (CBR), and objective response rate (ORR). RESULTS: Twenty-nine women (median age 60 years) participated; all but one were previously treated with a CDK4/6i (median duration 2 years). The lasofoxifene-abemaciclib combination was well tolerated with primarily grade 1/2 treatment-emergent adverse events (TEAEs), most commonly diarrhea, nausea, fatigue, and vomiting. One patient (with no prior CDK4/6i) discontinued treatment due to grade 2 diarrhea. No deaths occurred during the study. Median PFS was 56.0 weeks [95% confidence interval (CI) 31.9 weeks-not estimable; ∼13 months]; PFS rates at 6, 12, and 18 months were 76.1%, 56.1%, and 38.8%, respectively. CBR at 24 weeks was 65.5% (95% CI 47.3% to 80.1%). In 18 patients with measurable lesions, ORR was 55.6% (95% CI 33.7% to 75.4%). ESR1-mutant circulating tumor DNA (ctDNA) allele fraction decreased from baseline to week 4 in 21/26 (80.8%) patients. CONCLUSIONS: Lasofoxifene plus abemaciclib had an acceptable safety profile, was well tolerated, and exhibited meaningful antitumor activity in women with ESR1-mutated, ER+/HER2- mBC after disease progression on prior CDK4/6i. Observed decreases in ESR1-mutant ctDNA with lasofoxifene concordant with clinical response suggest target engagement. If the ELAINE 2 findings are confirmed in the initiated, phase III, ELAINE 3 trial, these data could be practice-changing and help address a critical unmet need.
引用
- Damodaran S, O'Sullivan CC, Elkhanany A, et al. Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. Ann Oncol. 2023. PMID: 38072513. doi:10.1016/j.annonc.2023.09.3103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。